KOVALTRY® in practice

Product Theater, Hall 2.2

Monday, 10 July, 2017 | 12:15-13:00

If you would like to attend this product theater, please select one of the options to receive a calendar invite.

Agenda

Welcome and introduction

12:15-12:20

Presented by Snejana Krassova,

Head of Medical Affairs Hematology, Bayer

 

PK in practice – what can we learn about KOVALTRY® from WAPPS?

12:20-12:35

Presented by Alfonso Iorio,

McMaster University, Ontario, Canada

 

Successfully integrating KOVALTRY® into clinical practice: Lessons from the Bonn HTC experience

12:35-12:50

Presented by Natascha Marquardt,

University Clinic, Bonn, Germany

 

Discussion and Q&A

12:50-13:00

▼ This medicinal product is subject to additional monitoring. Adverse events should be reported. Please report any suspected adverse reaction to your national authority. Please use the following website to find contact details of your respective local health authority: http://www.hma.eu/nationalcontacts_hum.html. Name of the medicinal product: Kovaltry 250 / 500 / 1000 / 2000 / 3000 IU powder and solvent for solution for injection (Refer to full SmPC before prescription.) Composition: Each vial contains nominally 250/500/1000/2000/3000 IU human coagulation factor VIII. Excipients: Sucrose, histidine, glycine, sodium chloride, calcium chloride and polysorbate 80. Indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Known allergic reactions to mouse or hamster proteins. Warnings and Precautions: Allergic type hypersensitivity reactions are possible. The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. Haemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-haemophilic patients when clotting has been normalised by treatment with FVIII. If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bactaeremia and catheter site thrombosis should be considered. Undesirable effects: common: lymphadenopathy, palpitation, sinus tachycardia, abdominal pain, abdominal discomfort, dyspepsia, pyrexia, chest discomfort, injection site reactions (incl. injection site extravasation, hematoma, infusion site pain, pruritus, swelling), headache, dizziness, insomnia, pruritus, rash (rash, rash erythematous, rash pruritic), dermatitis allergic; uncommon: hypersensitivity, dysgeusia, urticaria, flushing. On prescription only. Marketing Authorisation Holder: Bayer, 51368 Leverkusen, Germany. Date of revision of the underlying Prescribing Information: 04/2017.

© 2017 Bayer AG. All rights reserved. Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer. L.DE.MKT.SM.05.2017.5556 | G.MKT.SM.HEM.04.2017.1328